Establishing organoids from metastatic pancreatic cancer patients, the OPT-I study

Establishing organoids from metastatic pancreatic cancer patients, the OPT-I study - OPT-I

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55389

Enrollment

Registered

2017-11-15

Start date

2017-12-06

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic adenocarcinoma pancreatic cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients older than 18 years - Diagnosed with locally advanced pancreatic cancer or metastatic pancreatic cancer - Able to understand the information given - WHO 0-2

Exclusion criteria

Exclusion criteria: - Unfit for biopsies & blood analyses in palliative chemotherapy studies - Not able to give informed consent (language, intellectual capacities, etc.)

Design outcomes

Primary

Measure	Time frame
The development of organoids from biopsies of metastases or primary tumour tissue of pancreatic cancer. The response of the organoids will be assessed for correlation with clinical response.	—

Secondary

Measure	Time frame
The expression of bio markers in organoid, organotypic and xenograft models will be investigated. DNA/RNA profiles will be correlated to clinical and pathological characteristics such as therapy response, survival and TNM classification.	—

Countries

Netherlands

Outcome results